AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10067694
Drug: DTwP (whole-cell)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTwP (whole-cell) vaccine
Trial: 2378547
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride 10 mg daily
Trial: 2378547
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride 20 mg daily
Trial: 2378547
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride 30 mg daily
Trial: 2378547
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride (various doses)
Trial: 2378547
Drug: Fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine hydrochloride (doses over 0.3 mg/kg per day)
Trial: 19025
Drug: Lorazepam 4
RxNorm normalized name: lorazepam 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 4 mg/70 kg i.m.
Trial: 19025
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg/70 kg i.m.
Trial: 15354524
Drug: Alpha1‐adrenoceptor blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha1‐adrenoceptor blocker (Terazosin 2 mg qn) and Levo‐ofloxacin (0.2 bid)
Trial: 11571657
Drug: Intracavernous injection
RxNorm normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernous injection with prostaglandin E1
Trial: 9829447
Drug: Azelaic acid
RxNorm normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azelaic acid 20% cream and glycolic acid 15% or 20% lotion
Trial: 8008725
Drug: dicloxacillin 500
RxNorm normalized name: dicloxacillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dicloxacillin 500 mg 3 times a day
Trial: 8008725
Drug: dicloxacillin 250
RxNorm normalized name: dicloxacillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dicloxacillin 250 mg + probenecid 250 mg 3 times a day
Trial: 3619135
Drug: Enprofylline 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprofylline 2.5 mg/kg
Trial: 3619135
Drug: Theophylline (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (standard dose)
Trial: 22354147
Drug: Antihypertensive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive therapy for 13 months
Trial: 11182531
Drug: Lithium treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium treatment (acute administration for 7 days)
Trial: 7547043
Drug: 4% amethocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% amethocaine gel
Trial: 7963202
Drug: Carbamazepine (modal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (modal dose 300 mg/day)
Trial: 29226809
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (14,000 IU weekly)
Trial: 24257813
Drug: CYP450 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP450 genotype and antidepressant serum concentration
Trial: 24257813
Drug: Differences in
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Differences in antidepressant serum concentrations
Trial: 21190450
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no cell therapy)
Trial: 2444132
Drug: 2.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/kg propofol (Disoprivan)
Trial: 2444132
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg methohexital (Brevimytal)
Trial: 2444132
Drug: 1.4 microgram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.4 microgram fentanyl + 0.07 mg/kg droperidol (Thalamonal)
Trial: 27453037
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL isotonic drink
Trial: 27453037
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL water
Trial: 23678501
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of implementation intentions and self-efficacy (II+SE) group
Trial: 18721244
Drug: Entecavir 1
RxNorm normalized name: entecavir 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 1 mg/day
Trial: 12131216
Drug: HIVIGLOB 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVIGLOB 50 mg/kg
Trial: 12131216
Drug: HIVIGLOB 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVIGLOB 200 mg/kg
Trial: 12131216
Drug: HIVIGLOB 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVIGLOB 400 mg/kg
Trial: 7673302
Drug: Collagenase ointment
RxNorm normalized name: collagenase Topical Ointment
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Collagenase ointment with polymyxin B sulfate/bacitracin powder
Trial: 7673302
Drug: Silver sulfadiazine
RxNorm normalized name: Silver Sulfadiazine
DrugBank: Silver sulfadiazine (DB05245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver sulfadiazine cream (1%)
Trial: 1981681
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg twice daily for 4 weeks, then increased to 10 mg twice daily for another 4 weeks, followed by open-label felodipine 5-15 mg twice daily for 1 year.
Trial: 1981681
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg once daily for 4 weeks, then increased to 50 mg once daily for another 4 weeks.
Trial: 7376786
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g GABA (single dose)
Trial: 7376786
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g GABA (daily for 4 days)
Trial: 17000096
Drug: Bronchodilators (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators (5 mg salbutamol plus 500 microg ipratropium bromide nebulisation)
Trial: 17000096
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy (without bronchodilators)
Trial: 17000096
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oxygen and bronchodilators
Trial: 15087613
Drug: Alfentanil (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (target concentration, 80 ng/ml)
Trial: 9789907
Drug: Quetiapine fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine fumarate treatment
Trial: 26435375
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy arm of the ACCORD trial
Trial: 24780946
Drug: Hypolipidic diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypolipidic diet and phyto-supplement (group E)
Trial: 22492367
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of hazelnuts, chocolate, and potato chips (∼1100 kJ/d) for 12 weeks
Trial: 19195326
Drug: Elvitegravir/r (150/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvitegravir/r (150/100 mg once daily) plus etravirine (200 mg twice daily)
Trial: 12969695
Drug: Hormone therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone therapy (estradiol, 2 mg p.o., plus norethisterone acetate, 1 mg)
Trial: 10596203
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with fentanyl and midazolam
Trial: 6414682
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy program (specifics not provided)
Trial: 3970673
Drug: Endarterectomized superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endarterectomized superficial femoral artery (ESFA) patch angioplasty
Trial: 3970673
Drug: Vein patch
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vein patch
Trial: 22993919
Drug: Hopaten acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hopaten acid (40 mg/kg per day)
Trial: 22993919
Drug: Propofol-fentanyl total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-fentanyl total intravenous anesthesia (TIVA) without hopaten acid
Trial: 20036427
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg tranylcypromine
Trial: 20036427
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tranylcypromine
Trial: 17624978
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) plus referral to Gamblers Anonymous (GA)
Trial: 10796061
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) formulation of indapamide (2.5 mg)
Trial: 10796061
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release (SR) formulation of indapamide (1.5 mg)
Trial: 10796061
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release (SR) formulation of indapamide (1.5 mg) after repeated administration
Trial: 10796061
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) formulation of indapamide (2.5 mg) after repeated administration
Trial: 8891006
Drug: 10% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% urea ointment
Trial: 1795202
Drug: Long-acting calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting calcium antagonists
Trial: 31403596
Drug: Mind Over
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mind Over Matter: Healthy Bowels, Healthy Bladder (treatment group)
Trial: 17710289
Drug: Dentifrice A
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dentifrice A (523 microgF/g)
Trial: 17710289
Drug: Dentifrice B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice B (1,062 microgF/g)
Trial: 17710289
Drug: Dentifrice C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dentifrice C (1,373 microgF/g)
Trial: 12577455
Drug: Parenteral administration
RxNorm normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral administration of 30 g of alanyl‐glutamine dipeptide (Dipeptiven, Fresenius‐Kabi) from day +1 to day +14 or to discharge from hospital
Trial: 12577455
Drug: Isolated control
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated control group receiving isonitrogenous glutamine‐free amino acid solution from day +1 to day +14 or to discharge from hospital
Trial: 12577455
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition in dose of 26.5 kcal/kg and 1 g of amino acid/kg given to patients who did not reach adequate oral intake for 5 days
Trial: 10199111
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) titrated to a dose of 0.7 mg/kg
Trial: 1830259
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin delivery (15 units of insulin in 1% sodium glycocholate)
Trial: 6858980
Drug: Suppository group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository group
Trial: 26965165
Drug: 8-week, group-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week, group-based, behaviour-change programme with weekly 90-min sessions about healthy eating and physical activity
Trial: 24633809
Drug: MNRP1685A (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNRP1685A (7.5, 15, 24, and 36 mg/kg) with bevacizumab 15 mg/kg every 3 weeks (Arm A)
Trial: 24633809
Drug: MNRP1685A (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNRP1685A (12 and 16 mg/kg) with bevacizumab 10 mg/kg every 2 weeks and paclitaxel 90 mg/m(2) weekly (Arm B)
Trial: 24633809
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MNRP1685A with bevacizumab
Trial: 24399119
Drug: IDIProst® Gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDIProst® Gold (one capsule q24 h) for 3 months
Trial: 24399119
Drug: Serenoa repens
RxNorm normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serenoa repens 320 mg (one capsule q24h) for 3 months
Trial: 17953792
Drug: Lornoxicam (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (24 mg day(-1))
Trial: 17953792
Drug: Dipyrone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone (5 g day(-1))
Trial: 16904312
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy with vincristine and actinomycin D for 6 weeks
Trial: 10819345
Drug: Nonavalent protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonavalent protein conjugate pneumococcal vaccine (PnCV)
Trial: 1394200
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant interleukin 2
Trial: 7362696
Drug: Clofibate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofibate (2 g/day)
Trial: 30882846
Drug: Pioglitazone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone therapy
Trial: 29720113
Drug: Guideline-driven antiemetic
RxNorm normalized name: metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guideline-driven antiemetic therapy
Trial: 29720113
Drug: Single agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single agent antiemetic therapy with haloperidol
Trial: 26746868
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) administered via four monthly intravitreal injections and then as needed per protocol
Trial: 25155371
Drug: Bevacizumab (Avastin);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (Avastin); administered every 4 weeks, pro re nata.
Trial: 25155371
Drug: Dexamethasone implant
RxNorm normalized name: dexamethasone Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone implant (Ozurdex); administered every 16 weeks, pro re nata.
Trial: 25155371
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Bevacizumab and Dexamethasone implant)
Trial: 22368041
Drug: Proximal esophageal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proximal esophageal pH capsule
Trial: 20415839
Drug: Hyperbaric Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric Oxygen Therapy (HBO(2)T) administered in a course of 20 treatments at pressures between 1.75ATA and 2.5ATA daily for 60-120 min over 4 weeks
Trial: 18541979
Drug: donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil (5 mg, n=11 or 10 mg, n=1)
Trial: 16358411
Drug: Liuwei Dihuang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liuwei Dihuang pill (LWDH)
Trial: 16358411
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional treatment with prednisone and CTX)
Trial: 12869000
Drug: Custom-made screw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom-made screw implants with plaque control terminated at one implant and continued at the other implant after one month of abutment connection.
Trial: 12869000
Drug: Custom-made screw
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Custom-made screw implants with varying periods of plaque accumulation (7, 21, or 90 days).
Trial: 7970453
Drug: Low-dose RU
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose RU 486 (5 mg alternate days for four doses, beginning 3 days after the urinary LH surge)
Trial: 11317155
Drug: Clonidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (300 mg)
Trial: 10897972
Drug: Finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride 1 mg daily
Trial: 7640038
Drug: Intensive weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intensive weekly regimen of cisplatin (70-85 mg/m2)
Trial: 7640038
Drug: 3-weekly combination
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-weekly combination chemotherapy with cisplatin (75 mg/m2)
Trial: 7640038
Drug: 3-weekly regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-weekly regimen with cisplatin (20 mg/m2 for 5 days)
Trial: 28531469
Drug: Ezetimibe therapy
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe therapy
Trial: 19055335
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (once a week for 10 weeks, in addition to conservative treatment with medication)
Trial: 19055335
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment with medication only (control group)
Trial: 16899485
Drug: Subcutaneous treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous treprostinil monotherapy
Trial: 16899485
Drug: Subcutaneous treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous treprostinil in idiopathic pulmonary arterial hypertension (IPAH) patients
Trial: 10663618
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy with idarubicin, ara-C, etoposide
Trial: 10663618
Drug: IL-2 treatment
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IL-2 treatment arms (high-dose vs low-dose)
Trial: 2135254
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 400 mg ibuprofen
Trial: 2135254
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 600 mg ibuprofen with 2 x 6 mg dexamethasone
Trial: 30169605
Drug: HINE E-GEL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HINE E-GEL®
Trial: 28052915
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of CDCs
Trial: 28052915
Drug: Late CDC
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late CDC infusion in controls
Trial: 28052915
Drug: Overall CDC
RxNorm normalized name: CDC-801
DrugBank: CDC-801 (DB15640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall CDC infusion
Trial: 26107818
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus standard MMT
Trial: 16368038
Drug: Once-monthly ibandronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly ibandronate
Trial: 11952431
Drug: Remifentanil (R)
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil (R) administered in incremental dosages (0.1-0.25-0.5 microg/kg/min)
Trial: 11952431
Drug: Fentanyl (F)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl (F) 1.5 microg/kg and midazolam (M) titrated between 1 and 10 mg
Trial: 9467551
Drug: Threshold dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Threshold dose plus 1/2 ampoule of FSH